Biotechnology and Bioprocess Engineering

, Volume 15, Issue 5, pp 709–715

Current perspectives on therapeutic antibodies

  • Soomin Yoon
  • Yong-Sung Kim
  • Hyunbo Shim
  • Junho Chung
Review

DOI: 10.1007/s12257-009-3113-1

Cite this article as:
Yoon, S., Kim, YS., Shim, H. et al. Biotechnol Bioproc E (2010) 15: 709. doi:10.1007/s12257-009-3113-1

Abstract

Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy.

Keywords

efficacyimmunogenicityserum half-lifetherapeutic monoclonal antibody

Copyright information

© The Korean Society for Biotechnology and Bioengineering and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Soomin Yoon
    • 1
  • Yong-Sung Kim
    • 2
  • Hyunbo Shim
    • 3
  • Junho Chung
    • 1
  1. 1.Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine and Cancer Research InstituteSeoul National UniversitySeoulKorea
  2. 2.Department of Molecular Science and Technology, Division of Applied Chemistry and Biological EngineeringAjou UniversitySuwonKorea
  3. 3.Department of Life Science and Division of Life and Pharmaceutical SciencesEwha Womans UniversitySeoulKorea